Katherine Fuh

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Endometrial Neoplasms 83%
3. Survival 43%
4. Neoplasms 43%
5. Uterine Neoplasms 36%
6. Heterografts 33%
7. Neoplasm Metastasis 33%
8. Cancer Survivors 26%
9. Ovarian Epithelial Carcinoma 25%
10. Receptor Protein-Tyrosine Kinases 23%
11. Cardiogenic Shock 22%
12. Hemodynamics 21%
13. Randomized Controlled Trials 21%
14. Text Messaging 21%
15. Vasoconstriction 20%
16. Shock 20%
17. Weight Loss 19%
18. Mesenteric Ischemia 19%
19. Homologous Recombination 18%
20. Drug Therapy 17%
21. Paclitaxel 17%
22. Poly(ADP-ribose) Polymerase Inhibitors 16%
23. Obesity 16%
24. Renal Cell Carcinoma 15%
25. Recurrence 14%
26. Hemorrhagic Shock 14%
27. Therapeutics 14%
28. Angiotensins 14%
29. R428 compound 14%
30. Discoidin Domain Receptor 2 14%
31. Platinum 14%
32. Recombinational DNA Repair 13%
33. Proteogenomics 13%
34. entinostat 13%
35. Lymph Node Excision 13%
36. Renin 12%
37. isosorbide-5-mononitrate 12%
38. olaparib 12%
39. Radiotherapy 12%
40. DNA Repair-Deficiency Disorders 11%
41. Percutaneous Nephrostomy 11%
42. Weights and Measures 11%
43. Vulvar Neoplasms 11%
44. Counseling 10%
45. Perfusion 10%
46. Chorioamnionitis 10%
47. Hospice Care 10%
48. Misoprostol 10%
49. Ureteral Obstruction 10%
50. taxane 10%